• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一家社区教学医院中因肺炎球菌感染住院患者的肺炎球菌疫苗接种率

Pneumococcal Vaccination Rates Among Patients Hospitalized for Pneumococcal Infection at a Community Teaching Hospital.

作者信息

Mishra Shikha, Harimohan Hridya, Ayabe Kelly, Johnson Royce, Fang Michelle

机构信息

Internal Medicine/Infectious Disease, Kern Medical, Bakersfield, USA.

Internal Medicine, Kern Medical, Bakersfield, USA.

出版信息

Cureus. 2025 Aug 21;17(8):e90703. doi: 10.7759/cureus.90703. eCollection 2025 Aug.

DOI:10.7759/cureus.90703
PMID:40862030
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12372568/
Abstract

Background Historically, lower pneumococcal vaccination (PV) coverage in minority populations and those with newly diagnosed chronic medical conditions, and increased hospitalizations for pneumococcal infections at Kern Medical (KM), a teaching hospital that serves as a safety net in Bakersfield, California, we sought to identify potential missed opportunities for pneumococcal vaccination at KM. Methods This quality improvement review was conducted to evaluate the PV status of patients who were hospitalized for pneumococcal disease from January 2023 through June 2024. Eligibility for PV was based on the Centers for Disease Control and Prevention (CDC)'s 2025 adult immunization schedule. PV history was identified through the California Immunization Registry. The primary endpoint was PV coverage in patients hospitalized for pneumococcal disease. Secondary endpoints included 14-day all-cause mortality, length of stay (LOS), and opportunities for vaccination at KM prior to admission. Results Thirty-five patients were hospitalized for pneumococcal disease at KM, including 18 cases of bacteremia. The mean age was 54 years, 77% were male, and 54% were Hispanic/Latino. Twenty-five patients met CDC criteria for PV; however, 92% of these patients were unvaccinated (68%) or undervaccinated (24%). Eight patients died within 14 days of positive culture, seven of whom were unvaccinated but eligible for PV. Mean LOS was 14 days with seven ICU days. Of the 23 unvaccinated or undervaccinated patients, the most common criteria met for PV included age (70%), chronic liver disease or alcoholism (35%), and diabetes mellitus (26%); only four patients between 50-64 years met criteria based on age alone. Of these, only five had primary care encounters at KM within one year of admission. Discussion Despite significant improvement in general incidence and outcomes of pneumococcal disease due to PV, vaccination rates still lag in minority communities and those with underlying medical conditions. The resultant and potentially avoidable impact on mortality and healthcare resources should serve as a call-to-action for public health and key stakeholders, including community pharmacies, to capture and augment opportunities for vaccination in these vulnerable populations. Conclusion This quality improvement review underscores significant gaps in pneumococcal vaccination coverage among adults hospitalized with pneumococcal disease at a safety-net hospital. Despite clear eligibility, the vast majority of the patients remained unvaccinated or undervaccinated prior to admission. However, achieving meaningful improvement in vaccine uptake will require a collaborative effort by public health agencies, hospital systems, and community partners to build trust, reduce vaccine hesitancy, and implement sustainable, equity-centered vaccination initiatives.

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af58/12372568/a5f4b7591ff6/cureus-0017-00000090703-i05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af58/12372568/935a300cd391/cureus-0017-00000090703-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af58/12372568/8388abf57e36/cureus-0017-00000090703-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af58/12372568/db70cdac6fea/cureus-0017-00000090703-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af58/12372568/c1bdc10d0a20/cureus-0017-00000090703-i04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af58/12372568/a5f4b7591ff6/cureus-0017-00000090703-i05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af58/12372568/935a300cd391/cureus-0017-00000090703-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af58/12372568/8388abf57e36/cureus-0017-00000090703-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af58/12372568/db70cdac6fea/cureus-0017-00000090703-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af58/12372568/c1bdc10d0a20/cureus-0017-00000090703-i04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af58/12372568/a5f4b7591ff6/cureus-0017-00000090703-i05.jpg
摘要

背景 从历史上看,少数族裔人群以及新诊断出患有慢性疾病的人群中肺炎球菌疫苗接种(PV)覆盖率较低,而在加利福尼亚州贝克斯菲尔德市作为安全网的教学医院克恩医疗中心(KM),肺炎球菌感染导致的住院人数有所增加,我们试图确定KM医院肺炎球菌疫苗接种的潜在错失机会。方法 进行这项质量改进评估,以评估2023年1月至2024年6月因肺炎球菌疾病住院的患者的PV状况。PV资格基于疾病控制与预防中心(CDC)的2025年成人免疫接种时间表。通过加利福尼亚免疫登记系统确定PV病史。主要终点是因肺炎球菌疾病住院患者的PV覆盖率。次要终点包括14天全因死亡率、住院时间(LOS)以及入院前在KM医院的疫苗接种机会。结果 35名患者在KM医院因肺炎球菌疾病住院,其中18例为菌血症。平均年龄为54岁,77%为男性,54%为西班牙裔/拉丁裔。25名患者符合CDC的PV标准;然而,这些患者中有92%未接种疫苗(68%)或接种不足(24%)。8名患者在培养结果呈阳性后的14天内死亡,其中7名未接种疫苗但符合PV接种条件。平均住院时间为14天,其中7天在重症监护病房。在23名未接种或接种不足的患者中,符合PV接种标准最常见的因素包括年龄(70%)、慢性肝病或酗酒(35%)以及糖尿病(26%);只有4名50 - 64岁的患者仅基于年龄符合标准。其中,只有5名患者在入院前一年内曾在KM医院接受初级保健。讨论 尽管由于PV,肺炎球菌疾病的总体发病率和治疗结果有了显著改善,但少数族裔社区以及有基础疾病的人群的疫苗接种率仍然滞后。由此对死亡率和医疗资源产生的潜在可避免影响,应促使公共卫生部门和包括社区药房在内的关键利益相关者采取行动,抓住并增加这些弱势群体的疫苗接种机会。结论 这项质量改进评估凸显了在一家安全网医院中,因肺炎球菌疾病住院的成年人在肺炎球菌疫苗接种覆盖率方面存在的重大差距。尽管有明确的接种资格,但绝大多数患者在入院前仍未接种或接种不足。然而,要在疫苗接种率方面取得有意义的改善,需要公共卫生机构、医院系统和社区合作伙伴共同努力,建立信任,减少疫苗犹豫,并实施可持续的、以公平为中心的疫苗接种倡议。

相似文献

1
Pneumococcal Vaccination Rates Among Patients Hospitalized for Pneumococcal Infection at a Community Teaching Hospital.一家社区教学医院中因肺炎球菌感染住院患者的肺炎球菌疫苗接种率
Cureus. 2025 Aug 21;17(8):e90703. doi: 10.7759/cureus.90703. eCollection 2025 Aug.
2
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
3
Immunogenicity and seroefficacy of pneumococcal conjugate vaccines: a systematic review and network meta-analysis.肺炎球菌结合疫苗的免疫原性和血清效力:系统评价和网络荟萃分析。
Health Technol Assess. 2024 Jul;28(34):1-109. doi: 10.3310/YWHA3079.
4
Behavioral interventions to reduce risk for sexual transmission of HIV among men who have sex with men.降低男男性行为者中艾滋病毒性传播风险的行为干预措施。
Cochrane Database Syst Rev. 2008 Jul 16(3):CD001230. doi: 10.1002/14651858.CD001230.pub2.
5
Interventions targeted at women to encourage the uptake of cervical screening.针对女性的干预措施,以鼓励她们接受宫颈癌筛查。
Cochrane Database Syst Rev. 2021 Sep 6;9(9):CD002834. doi: 10.1002/14651858.CD002834.pub3.
6
Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.成人全身麻醉后预防术后恶心呕吐的药物:网状Meta分析
Cochrane Database Syst Rev. 2020 Oct 19;10(10):CD012859. doi: 10.1002/14651858.CD012859.pub2.
7
Falls prevention interventions for community-dwelling older adults: systematic review and meta-analysis of benefits, harms, and patient values and preferences.社区居住的老年人跌倒预防干预措施:系统评价和荟萃分析的益处、危害以及患者的价值观和偏好。
Syst Rev. 2024 Nov 26;13(1):289. doi: 10.1186/s13643-024-02681-3.
8
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中,如果患者出现以下症状和体征,可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.
9
Home treatment for mental health problems: a systematic review.心理健康问题的居家治疗:一项系统综述
Health Technol Assess. 2001;5(15):1-139. doi: 10.3310/hta5150.
10
Antibiotics for exacerbations of asthma.用于哮喘加重期的抗生素
Cochrane Database Syst Rev. 2018 Jun 25;6(6):CD002741. doi: 10.1002/14651858.CD002741.pub2.

本文引用的文献

1
Strategies for pneumococcal vaccination in older adults in the coming era.未来时代老年人肺炎球菌疫苗接种策略。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2328963. doi: 10.1080/21645515.2024.2328963. Epub 2024 Mar 22.
2
Pneumococcal vaccination coverage among adults newly diagnosed with underlying medical conditions and regional variation in the U.S.美国新诊断出基础疾病的成年人中肺炎球菌疫苗接种率及其地域差异
Vaccine. 2022 Aug 5;40(33):4856-4863. doi: 10.1016/j.vaccine.2022.06.068. Epub 2022 Jul 6.
3
Surveillance of Vaccination Coverage Among Adult Populations -United States, 2018.
成人人群疫苗接种覆盖率监测-美国,2018 年。
MMWR Surveill Summ. 2021 May 14;70(3):1-26. doi: 10.15585/mmwr.ss7003a1.
4
Influenza Vaccination Beliefs and Practices in Elderly Primary Care Patients.老年人初级保健患者中的流感疫苗接种信念和实践。
J Community Health. 2018 Feb;43(1):201-206. doi: 10.1007/s10900-017-0404-x.
5
Surveillance of Vaccination Coverage among Adult Populations - United States, 2015.2015年美国成年人群疫苗接种覆盖率监测
MMWR Surveill Summ. 2017 May 5;66(11):1-28. doi: 10.15585/mmwr.ss6611a1.
6
Pneumococcal vaccination.肺炎球菌疫苗接种。
Curr Opin Infect Dis. 2016 Apr;29(2):187-96. doi: 10.1097/QCO.0000000000000246.
7
U.S. physicians' perspective of adult vaccine delivery.美国医生对成人疫苗接种的看法。
Ann Intern Med. 2014 Feb 4;160(3):161. doi: 10.7326/M13-2332.
8
Clinical and economic burden of pneumococcal disease in older US adults.美国老年人肺炎球菌病的临床和经济负担。
Vaccine. 2010 Jul 12;28(31):4955-60. doi: 10.1016/j.vaccine.2010.05.030. Epub 2010 May 22.
9
Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine.在结合疫苗时代,侵袭性肺炎球菌病的持续减少。
J Infect Dis. 2010 Jan 1;201(1):32-41. doi: 10.1086/648593.
10
Vaccines for preventing pneumococcal infection in adults.用于预防成人肺炎球菌感染的疫苗。
Cochrane Database Syst Rev. 2008 Jan 23(1):CD000422. doi: 10.1002/14651858.CD000422.pub2.